Nephrocare Health Services Ltd.
NSE: NEPHROPLUS
Size band
Small cap
Market cap
5,301cr
P/E
154.8
ROE
7.4%
No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.
What management said
5 statements on recordEarnings call · Q1 FY27 · 19 Aug 2026
- medium-term growth→15% to 20%· over the next three to five years
“We continue to maintain our medium-term growth guidance of 15% to 20% over the next three to five years and remain focused on delivering sustainable and capital-efficient growth.”
- India clinic additions→40 to 50 clinics in India every year· every year
“We have indicated in our calls that we intend to open 40 to 50 clinics in India every year.”
- Philippines clinic additions→10 to 15 clinics in Philippines every year· every year
“10 to 15 clinics in Philippines every year.”
- new international market additions→a new international market every 12 to 18 months· every 12 to 18 months
“And we intend to open a new international market every 12 to 18 months.”
- new international market additions→a new international market every 12 to 18 months· every 12 to 18 months
“As we have stated before, it is, we aim to add a new international market every 12 to 18 months.”
Taken from management commentary on the company’s earnings call and quoted verbatim. These are statements of intent made by the company, not forecasts by Bharatstox, and nothing here records whether they were met.
No broadcast calls recorded.
We log calls made about a company on business television — Zee Business, CNBC Awaaz and NDTV Profit — as they are stated on air. Nothing is on record for Nephrocare Health Services Ltd..
Shareholding
change across 4 filings| Category | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Change |
|---|---|---|---|---|---|
| Promoters | 58.3 | 63.9 | 63.9 | 63.9 | −5.6 |
| Foreign institutions | 11.7 | 8.8 | 9.9 | 9.3 | +2.4 |
| Domestic institutions | 8.1 | 9.1 | 8.7 | 8.1 | 0.0 |
| Retail & others | 21.9 | 18.3 | 17.6 | 18.8 | +3.1 |
As filed with the exchange for the periods ending Dec 25 to Sep 26.
Filings
latest 25 of 100- Certificate under SEBI (Depositories and Participants) Regulations, 20187 Oct 2026
- Trading Window25 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates22 Sept 2026
- Pursuant to Reg 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an investor conference call as per the disclosure annexed herewith.22 Sept 2026
- Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform the update on Credit Ratings of the Company received from India Ratings and Research Private Limited as per the disclosure ....18 Sept 2026
- Credit Rating- Revision18 Sept 2026
- Other Restructuring18 Sept 2026
- Disclosure under Reg 30 of SEBI Listing Regulations -Rationalisation and Consolidation of Company''s Step-down Subsidiaries in the Philippines as per the disclosure annexed herewith.18 Sept 2026
- Agreements14 Sept 2026
- Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform you that Nephrocare Health Services, Philippines Inc., a step-down wholly owned subsidiary of the Company has acquired a ....14 Sept 2026
- Options to purchase securities3 Sept 2026
- We hereby inform that the Company has approved grant of ESOPs under the Scheme as per the disclosure annexed herewith.3 Sept 2026
- Agreements1 Sept 2026
- Pursuant to Reg 30 of SEBI Listing Regulations, we wish to hereby inform that NephroPlus Health Services Kazakhstan LLP, an overseas subsidiary of the Company has entered into a Share Purchase ....1 Sept 2026
- Pursuant to Regulation 30 of SEBI Listing Regulations, we hereby inform that the Company has received Tax demand pursuant to Tax Audit as per the annexed disclosure.31 Aug 2026
- Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company31 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates19 Aug 2026
- Agreements17 Aug 2026
- Shareholders meeting13 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates13 Aug 2026
- Agreements13 Aug 2026
- Disclosure of material issue12 Aug 2026
- Shareholders meeting12 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates12 Aug 2026
- Monitoring Agency Report11 Aug 2026
The 25 most recent of 100 filings we hold for NEPHROPLUS, back to January 2024. Every filing, by day.
Disclaimer
Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.